

FUTUREPHARMA

RESPONDING TO THE NEED FOR LOCAL PHARMACEUTICAL PRODUCTION

AN OPEN INNOVATION FACILITY INTEGRATING CONTINUOUS PHARMACEUTICAL MANUFACTURING AND BIOPHARMACEUTICAL PRODUCTION

PRIVATE SECTOR

16% of the population (**9 million people**) can afford high quality private healthcare



PUBLIC SECTOR

Services **84%** of the population (**48 million people**)



9 MILLION PEOPLE

84% of the total pharma expenditure

Private healthcare is available through medical aid schemes




48 MILLION PEOPLE

16% of the total pharma expenditure

Public health is financed through the government, primarily through taxes



CROSS-CUTTING: BUSINESS DEVELOPMENT AND COMMERCIALISATION SUPPORT



AN INDUSTRY LIKE ENVIRONMENT WHERE;

- Innovators in the region can access specialized infrastructure, skills, systems and processes to turn their ideas and concepts into prototypes for clinical development using a variety of technologies (bacteria, yeast, plant, and mammalian expression systems, and batch-flow-biocatalytic hybrid small molecule production)
- Key differentiator and competitive advantage is the integration of a wide variety of technologies to provide digitally enabled, integrated end-to-end processing technology for active pharmaceutical ingredient production
- cGMP capabilities provide a strategic capability to develop investigational clinical-grade biopharmaceutical materials at pilot scale for clinical testing and emergency use
- Skills can be developed along the research and development value chain, with requisite techno-economics from the lab to the clinic
- Platform for local and international collaboration